ArticleMethods in molecular biology (Clifton, N.J.)2023
Assessing the Challenges of Nanotechnology-Driven Targeted Therapies: Development of Magnetically Directed Vectors for Targeted Cancer Therapies and Beyond.
Article in Methods in molecular biology (Clifton, N.J.), 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed, 3 citations in OpenAlex.
- Iron-Oxide Labeled Stem Cells with Specific Magnetic Occurrence for Effective in Mouse Model of Cisplatin-Induced Acute Kidney Injury.International journal of nanomedicine · 2025Article
- A novel degradable PEG superparamagnetic iron oxide capsule coupled with a polyphenolic nano-enzymatic conjugate (PSPM-NE), to treat ROS-driven cardiovascular-diseases, tested in atherosclerosis as a model disease, and hypothesizing autoimmunity as an atheroma's trigger.Frontiers in cardiovascular medicine · 2024Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
1 author at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Targeted delivery, in which therapeutic agents are preferentially concentrated at the diseased site, has the potential to improve therapeutic outcomes by minimizing off-target interactions in healthy tissue. Both passive and active methods of targeting delivery have been proposed, often with particular emphasis on cancer treatment. Passive methods rely on the overexpression of a biomarker in diseased tissue that can then be used to target the therapy. Active techniques involve physically guiding therapeutic agents toward the target region. Since the motion of magnetic particles can be remotely controlled by external magnetic fields, magnetic technologies have the potential to drive and hold drugs or other cargo at the required therapeutic site, increasing the localized dose while minimizing overall exposure. Directed motion may be generated either by simple magnetic attraction or by causing the particles to perform swimming strokes to produce propulsion. This chapter will compare the different strategies using magnetic nanotechnology to produce directed motion compatible with that required for targeted cargo delivery and magnetically assisted therapies and assess their potential to meet the challenges of operating within the human body.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.